|
1
|
Peleg AY, Weerarathna T, McCarthy JS and
Davis TM: Common infections in diabetes: Pathogenesis, management
and relationship to glycaemic control. Diabetes Metab Res Rev.
23:3–13. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Spellberg B, Edwards J Jr and Ibrahim A:
Novel perspectives on mucormycosis: Pathophysiology, presentation,
and management. Clin Microbiol Rev. 18:556–569. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chinn RY and Diamond RD: Generation of
chemotactic factors by Rhizopus oryzae in the presence and absence
of serum: Relationship to hyphal damage mediated by human
neutrophils and effects of hyperglycemia and ketoacidosis. Infect
Immun. 38:1123–1129. 1982.PubMed/NCBI
|
|
4
|
Ibrahim AS, Gebermariam T, Fu Y, Lin L,
Husseiny MI, French SW, Schwartz J, Skory CD, Edwards JE Jr and
Spellberg BJ: The iron chelator deferasirox protects mice from
mucormycosis through iron starvation. J Clin Invest. 117:2649–2657.
2007. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ibrahim AS: Host cell invasion in
mucormycosis: Role of iron. Curr Opin Microbiol. 14:406–411. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cagatay AA, Oncü SS, Calangu SS, Yildirmak
TT, Ozsüt HH and Eraksoy HH: Rhinocerebral mucormycosis treated
with 32 gram liposomal amphotericin B and incomplete surgery: A
case report. BMC Infect Dis. 1:222001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ericsson M, Anniko M, Gustafsson H, Hjalt
CA, Stenling R and Tärnvik A: A case of chronic progressive
rhinocerebral mucormycosis treated with liposomal amphotericin B
and surgery. Clin Infect Dis. 16:585–586. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pfaller MA, Messer SA, Hollis RJ and Jones
RN: SENTRY Participants Group: Antifungal activities of
posaconazole, ravuconazole, and voriconazole compared to those of
itraconazole and amphotericin B against 239 clinical isolates of
Aspergillus spp. and other filamentous fungi: Report from SENTRY
Antimicrobial Surveillance Program, 2000. Antimicrob Agents
Chemother. 46:1032–1037. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sun QN, Fothergill AW, McCarthy DI,
Rinaldi MG and Graybill JR: In vitro activities of posaconazole,
itraconazole, voriconazole, amphotericin B, and fluconazole against
37 clinical isolates of zygomycetes. Antimicrob Agents Chemother.
46:1581–1582. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yoon YK, Kim MJ, Chung YG and Shin IY:
Successful treatment of a case with rhino-orbital-cerebral
mucormycosis by the combination of neurosurgical intervention and
the sequential use of amphotericin B and posaconazole. J Korean
Neurosurq Soc. 47:74–77. 2010. View Article : Google Scholar
|
|
11
|
Rybak JM, Marx KR, Nishimoto AT and Rogers
PD: Isavuconazole: Pharmacology, pharmacodynamics, and current
clinical experience with a new triazole antifungal agent.
Pharmacotherapy. 35:1037–1051. 2015. View Article : Google Scholar : PubMed/NCBI
|
